Patient and physician education, trust-building, and support mechanisms are needed to reduce barriers to clinical trial participation for Black people with sarcoidosis, according to a paper by the Foundation for Sarcoidosis Research (FRS). The white paper was titled “Ignore No More Campaign on Clinical Trials…
News
Bellerophon Therapeutics is working toward launching a new Phase 2 trial to test INOpulse, its experimental device for inhaled nitric oxide, in people who develop pulmonary hypertension as a complication of sarcoidosis (PH-Sarc). The announcement was part of a company’s clinical program update that stated…
About six months with Acthar Gel were associated with greater therapeutic benefits than a placebo in people with pulmonary sarcoidosis receiving standard-of-care therapies, including glucocorticoids, data from a Phase 4 trial show. The benefits were sustained in those who continued treatment in an extension phase and became evident…
Swelling of a specific vein in the brain may be a sign of neurosarcoidosis, a form of sarcoidosis that affects the nervous system, a new study suggests. “Incorporating this in the current diagnostic criteria may result in timely intervention, and we encourage radiologists to look for this marker in patients…
Only about half of sarcoidosis patients showing signs of muscle disease, or myopathy, have the small clumps of immune cells in their muscles that characterize sarcoidosis, a study showed. When these clumps, called granulomas, weren’t present with muscle symptoms, myopathy was most often linked to inclusion body myositis (IBM),…
The risk of sarcoidosis is significantly reduced in people who smoke cigarettes and may be increased in people who are obese, a study in Sweden suggested. While these findings are consistent with some previous studies, more research is needed to confirm them, the researchers noted in “Modifiable lifestyle…
A lung bleeding condition called diffuse alveolar hemorrhage (DAH) may develop secondary to sarcoidosis more frequently than previously reported, a small study suggests. Considering the frequency of DAH associated with sarcoidosis reported in the study, “it is essential to consider sarcoidosis in the differential diagnosis of immune-mediated DAH,” the researchers…
The Foundation for Sarcoidosis Research (FSR) is offering ways to participate in National Sarcoidosis Awareness Month, observed each April, to call attention to sarcoidosis and the 175,000 U.S. residents thought to be living with the disease. Despite advances in research, sarcoidosis remains challenging to diagnose and…
In advance of Sarcoidosis Awareness Month in April, the Foundation for Sarcoidosis Research (FSR) and aTyr Pharma will hold a virtual town hall about sarcoidosis and considerations for transitioning from standard corticosteroids to new therapies. The meeting, which is open to anyone, will be held online at…
The Foundation for Sarcoidosis Research (FSR) has trained its first group of volunteer patients tasked with educating and championing better treatments and outcomes for people living with sarcoidosis in the U.S. The 60 newly trained volunteer leaders will team up with and support members of the foundation’s…
Recent Posts
- Global sarcoidosis network expands to 55 institutions worldwide
- We need to keep sharing our stories and reject the ‘sickfluencer’ narrative
- Cell-released proteins may predict sarcoidosis treatment response
- Registry study finds heart sarcoidosis outcomes vary by feature
- Critical conversations: Why talking about our medications is essential
- Study challenges theory of microbes as sarcoidosis cause
- FDA, developer align on protocols for trial of pulmonary sarcoidosis drug
- Large study ties sarcoidosis to risk of permanent liver scarring
- Reflecting with gratitude on what sarcoidosis has brought to my life
- Lingering heart inflammation tied to cardiac sarcoidosis relapse risk